Supplementary tables: Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations inParkinson’s disease: a systematic review and meta-analysis

These are peer-reviewed supplementary materials for the article 'Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson’s disease: a systematic review and meta-analysis' published in the Journal of Comparative Effectiveness Research.Table S1: Keywords used in the searches of medical databases to identify relevant studies for opicapone for the treatment of patients with Parkinson’s diseaseTable S2: Basic characteristics of the studies included in the meta-analysisAim: To assess the clinical efficacy and safety profile of opicapone (25 and 50 mg once daily) versus placebo. Patients: Levodopa-treated adults with Parkinson’s disease. Material & methods: A systematic review and meta-analysis were conducted. Results: Opicapone provided a greater reduction in the absolute OFF-time, increased the chances of ≥1-h reduction in the OFF-time and ≥1-h increase in the ON-time compared with placebo. Receiving opicapone more often facilitated levodopa dose reduction versus placebo. There were no differences in the occurrence of adverse events (severe and leading to drug discontinuation), but receiving opicapone increased the frequency of dyskinesia. Conclusion: Opicapone demonstrated superior clinical efficacy to placebo, with a comparable general safety profile.

本数据集为发表于《比较疗效研究杂志》的论文《Opicapone作为左旋多巴的辅助治疗以减少帕金森病患者的末次给药运动波动：一项系统综述和荟萃分析》的同行评审补充材料。表S1：用于识别Opicapone治疗帕金森病患者相关研究的医学数据库搜索关键词；表S2：纳入荟萃分析的研究的基本特征。研究目的：评估Opicapone（25mg和50mg，每日一次）与安慰剂相比的临床疗效和安全性。研究对象：接受左旋多巴治疗的帕金森病成人患者。研究方法：进行了一项系统综述和荟萃分析。研究结果：与安慰剂相比，Opicapone显著降低了绝对“关”时间，增加了≥1小时“关”时间减少和≥1小时“开”时间增加的几率。较之安慰剂，更频繁地接受Opicapone治疗更有利于左旋多巴剂量的减少。在不良事件（严重且导致药物停用）的发生率上两组无显著差异，但接受Opicapone治疗的患者肌张力障碍的发生频率有所增加。研究结论：Opicapone在临床疗效上优于安慰剂，且总体安全性相当。